Selected data models

You must log in to select data models for download or further analysis.

71 Search results.
Relevance Rating New first Old first

Eligibility Cancer NCT00708448

- 11/9/17 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00708448

Eligibility Cancer NCT00630110

- 11/9/17 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00630110

Eligibility Lung Cancer NCT00955175

- 9/20/21 - 1 form, 1 itemgroup, 11 items, 1 language
Itemgroup: Criteria
Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09; ODM derived from: https://clinicaltrials.gov/show/NCT00955175

Eligibility Lung Cancer NCT00653250

- 1/19/16 - 1 form, 1 itemgroup, 16 items, 1 language
Itemgroup: Criteria
Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00653250

dbGaP phs000855 Resistance studies in Lung Cancer - pht004553.v1.p1

- 3/16/24 - 5 forms, 1 itemgroup, 2 items, 1 language
Itemgroup: pht004553
Principal Investigator: Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA MeSH: Carcinoma,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000855 The purpose of the study was to compare gene expression profiles from a cohort of crizotinib-resistant ALK-rearranged lung tumors and a cohort of treatment-naive ALK-rearranged lung tumors. Expression profiles were generated by RNA-seq. In parallel, gene expression profiles were obtained from ALK-rearranged lung cancer cell lines in the presence or absence of the ALK inhibitor TAE684. Gene expression profiles were also obtained from ALK-rearranged cells ectopically expressing genes associated with ALK inhibitor resistance that were identified from a functional genetic study.

pht004554.v1.p1

1 itemgroup 3 items

pht004552.v1.p1

1 itemgroup 3 items

Eligibility

1 itemgroup 1 item

pht004551.v1.p1

1 itemgroup 2 items

Lung Cancer Smoking Survey NCT00324805 - Follow Up Smoking Survey Lung Cancer NCT00324805 ECOG-E1505

- 3/25/15 - 1 form, 3 itemgroups, 21 items, 1 language
Itemgroups: Header, Smoking status, Nic Alert Test Result
ECOG-E1505 Follow Up Smoking Survey Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery NCT00324805 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0745B0C2-1A2A-5046-E044-0003BA3F9857

dbGaP phs000299 Genentech Lung Cancer Sequencing - pht001553.v2.p1

- 10/12/22 - 6 forms, 1 itemgroup, 5 items, 1 language
Itemgroup: pht001553
Principal Investigator: Zemin Zhang, PhD, Genentech Inc., South San Francisco, CA, USA MeSH: Lung Neoplasms,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000299 Version 1 Whole genome sequencing was applied to tumor and adjacent normal lung tissue in an individual non-small-cell lung cancer patient. We present an analysis of somatic changes identified throughout the tumor genome, including single-nucleotide variants, copy number variants, and large-scale chromosomal rearrangements. Over 50,000 high-confidence single-nucleotide variants were identified, revealing evidence of substantial smoking-related DNA damage as well as distinct mutational pressures within the tumor resulting in uneven distribution of somatic mutations across the genome. Version 2 Lung cancer is a highly heterogeneous disease in terms of both underlying genetic lesions and response to therapeutic treatments. We performed deep whole genome sequencing and transcriptome sequencing on 19 lung cancer cell lines and 3 lung tumor/normal pairs. Overall, our data show that cell line models exhibit similar mutation spectra to human tumor samples. Smoker and never-smoker cancer samples exhibit distinguishable patterns of mutations. A number of epigenetic regulators are frequently altered by mutations or copy number changes. A systematic survey of splice-site mutations identified over 100 splice site mutations associated with cancer specific aberrant splicing, including mutations in several known cancer-related genes. Differential usages of splice isoforms were also studied. Taken together, these data present a comprehensive genomic landscape of a large number of lung cancer samples and further demonstrate that cancer specific alternative splicing is a widespread phenomenon that has potential utility as therapeutic biomarkers.

pht001881.v2.p1

1 itemgroup 2 items

pht001882.v2.p1

1 itemgroup 7 items

pht001551.v2.p1

1 itemgroup 5 items

pht001552.v2.p1

1 itemgroup 5 items

Eligibility

1 itemgroup 4 items

Eligibility NCT00858364 Non-Small Cell Lung Cancer - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 33 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00858364

Eligibility NCT00981058 Non Small Cell Lung Cancer - Eligibility

- 9/17/21 - 1 form, 2 itemgroups, 30 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00981058

Eligibility NCT00982111 Non Small Cell Lung Cancer - Eligibility

- 9/17/21 - 1 form, 2 itemgroups, 29 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00982111

Eligibility Non-small Cell Lung Cancer NCT00569114

- 8/16/17 - 1 form, 1 itemgroup, 12 items, 1 language
Itemgroup: Criteria
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00569114

Eligibility Non-Small-Cell Lung Cancer NCT01037998

- 5/22/17 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01037998

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial